• ABOUT US
  • CONTACT
  • TEAM
  • TERMS & CONDITIONS
  • GUEST POSTS
Wednesday, October 1, 2025
  • Login
Economy India
No Result
View All Result
  • Home
  • Economy
  • Business
  • Companies
  • Finance
  • People
  • More
    • Insurance
    • Interview
    • Featured
    • Health
    • Technology
    • Entrepreneurship
    • Opinion
    • CSR
    • Stories
  • Home
  • Economy
  • Business
  • Companies
  • Finance
  • People
  • More
    • Insurance
    • Interview
    • Featured
    • Health
    • Technology
    • Entrepreneurship
    • Opinion
    • CSR
    • Stories
No Result
View All Result
Economy India
No Result
View All Result
Home Economy

Trump Slaps 100% Tariff on Branded Drugs from October 1; India, Key Exporter, Faces Uncertainty

by Economy India
September 26, 2025
Reading Time: 5 mins read
Trump Slaps 100% Tariff on Branded Drugs from October 1; India, Key Exporter, Faces Uncertainty

Trump Slaps 100% Tariff on Branded Drugs from October 1; India, Key Exporter, Faces Uncertainty

SHARESHARESHARESHARE


Washington, Sept 15 (Economy India): US President Donald Trump has announced a 100% tariff on all branded or patented pharmaceutical imports, effective October 1, 2025. The move, part of his aggressive “America First” and “Make in America” strategy, aims to push global pharma companies to set up manufacturing plants within the United States.

The new tariff will not apply to companies that already operate or are in the process of setting up drug manufacturing facilities in the US.

ADVERTISEMENT

India Among the Most Affected Exporters

India, one of the world’s largest drug exporters, ships nearly 30% of its total pharmaceutical exports to the US. In 2024, India exported medicines worth $8.73 billion (approx. ₹77,000 crore) to America. While much of this consists of generic drugs, Indian firms also export branded formulations, which could be hit by the new tariffs.

Trump has already imposed a 50% tariff on Indian exports such as textiles, gems & jewelry, seafood, and furniture from August 27. Pharmaceuticals had been excluded until now, but this latest decision places branded medicines squarely in the line of fire.

Trump Slaps 100% Tariff on Branded Drugs from October 1; India, Key Exporter, Faces Uncertainty
Trump Slaps 100% Tariff on Branded Drugs from October 1; India, Key Exporter, Faces Uncertainty

Trump’s Rationale: Boost Domestic Manufacturing

In his announcement, Trump said:

“From October 1, we will impose a 100% tariff on branded or patented drugs, except for those companies that are building or already have plants in the US. America cannot afford to rely on other countries for essential medicines. This is about national security and strengthening our supply chain.”

The Trump administration has argued that heavy dependence on imports poses risks to the US healthcare system. The COVID-19 pandemic had highlighted vulnerabilities in the global supply chain when drug shortages threatened patient care.


Generics Exempt—for Now

Interestingly, generic medicines have been spared from the tariff, at least for now. Analysts believe this is because US healthcare is heavily dependent on low-cost generics, which are 80–90% cheaper than branded drugs.

According to a report, 4 out of every 10 prescriptions filled in the US are supplied by Indian pharma companies. Between 2013 and 2022, the US healthcare system saved $1.3 trillion by using generics.

However, experts warn that generics could be Trump’s next target.
“While India may not feel a big impact immediately, the possibility of tariffs on generics in the future cannot be ruled out. This would have a direct effect on both pharma stocks and the healthcare sector in the US,” said V.K. Vijayakumar, Chief Investment Strategist at Geojit Investments.


Branded vs. Generic: Key Difference

  • Branded (Patented) Drugs: Developed through years of costly research, protected by patents for around 20 years, and priced significantly higher to recover R&D investments.
  • Generic Drugs: Manufactured after patents expire, using the same formula. They cost 80–90% less since no R&D investment is required.
Trump Slaps 100% Tariff on Branded Drugs from October 1; India, Key Exporter, Faces Uncertainty
Trump Slaps 100% Tariff on Branded Drugs from October 1; India, Key Exporter, Faces Uncertainty

Impact on Indian Pharma Giants

Indian companies like Sun Pharma, Dr. Reddy’s, and Lupin export both generics and some branded drugs to the US. Analysts say while generics remain unaffected, these firms’ branded product lines could face additional costs, impacting competitiveness.

For consumers in the US, the move could lead to higher drug prices if multinational pharma firms fail to localize production quickly.


Wider Trade Actions: Furniture, Cabinets, and Trucks

Trump also expanded tariffs on other imports:

  • 50% on kitchen cabinets, bathroom vanities, and related goods starting October 1.
  • 30% on upholstered furniture such as sofas and cushioned chairs.
  • 25% on heavy trucks manufactured outside the US, aimed at protecting American truck makers like Peterbilt, Kenworth, and Mack Trucks.

“These countries are flooding our markets with unfair exports,” Trump said. “We must protect American workers and industries.”


Outlook

  • For India, the move underscores the increasing unpredictability of US trade policy.
  • While generics remain untouched, the threat of future tariffs looms large.
  • Pharma firms may need to consider setting up plants in the US to bypass tariffs.
  • In the short term, stock market volatility in Indian pharma shares is expected.

Trump’s escalating tariff war has opened a new front—pharmaceuticals—where India plays a critical role. Whether generics remain exempt or not could decide the extent of the long-term impact on India’s $25 billion pharma export industry.

(Economy India)

Source: Economy India
Tags: Branded Drugs TariffEconomy IndiaGeneric MedicinesIndian Pharma ExportsMake in AmericaPharmaceutical IndustryTrump Tariff 2025 US India TradeUS Trade Policy
Economy India

Economy India

Economy India is one of the largest media on the Indian economy. It provides updates on economy, business and corporates and allied affairs of the Indian economy. It features news, views, interviews, articles on various subject matters related to the economy and business world.

Related Posts

India Extends Export Duty and Tax Refund Scheme (RoDTEP) Until March 2026: A Comprehensive Analysis
Economy

India Extends Export Duty and Tax Refund Scheme (RoDTEP) Until March 2026: A Comprehensive Analysis

September 30, 2025
GST 2.0: FMCG Firms Expect Full Price Alignment Within Two Months
Economy

GST 2.0: FMCG Firms Expect Full Price Alignment Within Two Months

September 24, 2025
India Reaffirms WTO-Centric Fair Trade System at SCO Ministers’ Meet, Showcases Digital Public Infrastructure
Economy

India Reaffirms WTO-Centric Fair Trade System at SCO Ministers’ Meet, Showcases Digital Public Infrastructure

September 8, 2025
For now, India remains resolute. As Puri concluded: “Our duty is to the Indian consumer. We will continue to act responsibly, but always in India’s interest.”
Economy

India Hits Back at U.S. on Russian Oil: “Followed Global Rules, Stabilized Market”

September 7, 2025
Designed in India, Made in India, Trusted by World: PM Modi at Semicon India 2025
Economy

Designed in India, Made in India, Trusted by World: PM Modi at Semicon India 2025

September 2, 2025
India-China Relations on the Path to Normalcy: Trade, Border Issues, and the Road Ahead
Economy

India-China Relations on the Path to Normalcy: Trade, Border Issues, and the Road Ahead

September 2, 2025
Next Post
TikTok Deal Gets Trump’s Nod: US Business to Be Sold for $14 Billion, Oracle to Oversee Data Security

TikTok Deal Gets Trump’s Nod: US Business to Be Sold for $14 Billion, Oracle to Oversee Data Security

I AM PEACEKEEPER I AM PEACEKEEPER I AM PEACEKEEPER
ADVERTISEMENT

LATEST NEWS

Kotak Mahindra Bank Named Best Private Sector Bank at Financial Express Best Banks Awards 2023–24

India Extends Export Duty and Tax Refund Scheme (RoDTEP) Until March 2026: A Comprehensive Analysis

Govt. Announces Diwali Bonus for Central Employees: ₹6,908 Payout, Railway Staff to Receive 78 Days PLB

Indian Economy to Grow at 6.5% in FY 2025-26 Despite Strong Q1 Performance: ADB

Sahara Seeks Supreme Court Nod to Sell 88 Properties to Adani Group; Proceeds to Repay ₹24,030 Crore Investor Dues

Crude Oil Futures Jump ₹25 on Strong Overseas Demand, MCX Sees Active Trading

Tax Audit Report Submission Deadline Extended to October 31 for FY 2024-25; ITR Filing Deadline Remains Unchanged

Reliance Consumer Products Signs ₹40,000 Crore MoU with Government to Build Integrated Food Manufacturing Facilities Across India

  • ABOUT US
  • CONTACT
  • TEAM
  • TERMS & CONDITIONS
  • GUEST POSTS

Copyright © 2024 - Economy India | All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Economy
  • Business
  • Companies
  • Finance
  • People
  • More
    • Insurance
    • Interview
    • Featured
    • Health
    • Technology
    • Entrepreneurship
    • Opinion
    • CSR
    • Stories

Copyright © 2024 - Economy India | All Rights Reserved